

Based on Form PTO-1449

(3/90)

ATTY. DOCKET NO.

SERIAL NO.

144002-2001

09/862,404

APPLICANT

Douglas T. Dieterich

FILING DATE


May 21, 2001

GROUP

1647  
1646

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RP	AA	6,172,046 B1	1/9/01	Albrecht			
	AB	5,610,054	3/11/97	Draper			
	AC	5,869,253	2/9/99	Draper			
	AD	6,132,966	10/17/00	Draper			
	AE	5,399,551	3/21/95	Ise et al.			
	AF	5,604,198	2/18/97	Poduslo et al.			
	AG	5,670,477	9/23/97	Poduslo et al.			
	AH	5,661,125	8/26/97	Strickland			
	AI	6,063,772	5/16/00	Tam			
	AJ	5,543,390	8/6/96	Yatvin et al.			
	AK	5,543,391	8/6/96	Yatvin et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AL		Abels RJ, Larholt KM, Krantz KD, et al., "Recombinant Human Erythropoietin (rHuEPO) for the Treatment of the Anemia of Cancer," <i>The Oncologist</i> , 1996, Vol. 1, pp. 140-50.
AM		Alter MJ, Kruszon-Moran D, Nainan OV, et al., "The Prevalence of Hepatitis C Virus Infection in the United States, 1988 Through 1994," <i>New England Journal of Medicine</i> , 1999, Vol. 341, pp. 556-62.
AN		Alter MJ, Mast EE, Moyer LA, et al., "Hepatitis C," <i>Infectious Disease Clinics of North America</i> , 1998, Vol. 12, pp. 13-26.
AO		Baer AN, Dessypris EN, Goldwasser E, et al., "Blunted Erythropoietin Response to Anaemia in Rheumatoid Arthritis," <i>British Journal of Haematology</i> , 1987, Vol. 66, pp. 559-64.
AP		Beguin Y, "Erythropoietin and the Anemia of Cancer," <i>Acta Clinica Belgica</i> 1996, Vol. 51, pp. 36-52.
AQ		Causse X, Godinot H, Chevallier M, et al., "Comparison of 1 or 3 MU of Interferon Alfa-2b and Placebo in Patients with Chronic Non-A, Non-B Hepatitis," <i>Gastroenterology</i> , 1991, Vol. 101, pp. 497-502.
AR		Cazzola M, Mercuriali F, Brugnara C, "Use of Recombinant Human Erythropoietin Outside the Setting of Uremia," <i>Blood</i> , 1997, Vol. 89, pp. 4248-67.
AS		Davis GL, Balart LA, Schiff ER, et al., "Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa: A Multicenter Randomized, Controlled Trial," <i>New England Journal of Medicine</i> , 1989, Vol. 321, pp. 1501-6.
AT		Dawson-Saunders B, Trapp RG, <i>Basic and Clinical Biostatistics</i> , Appleton & Lange, Norwalk, CT, 1990.*
AU		Di Bisceglie AM, Martin P, Kassianides C, et al., "Recombinant Interferon Alfa Therapy for Chronic Hepatitis C: A Randomized, Double-Blind, Placebo-Controlled Trial," <i>New England Journal of Medicine</i> , 1989, Vol. 321, pp. 1506-10.
AV		Elghetany MT, Davey FR, "Erythrocytic Disorders," <i>Clinical Diagnosis and Management by Laboratory Methods</i> , 19 <sup>th</sup> Ed. (Henry JB, ed.), WB Saunders Company, Philadelphia, 1996, pp. 617-63.
AW		Fisher JW, "Erythropoietin: Physiologic and Pharmacologic Aspects," <i>Proceedings of the Society for Experimental Biology and Medicine</i> , 1997, Vol. 216, pp. 358-69.

AX	Gogu SR, Beckman BS, Wilson RB, et al., "Inhibitory Effects of Zidovudine in Erythroid Progenitor Cells: Reversal with a Combination of Erythropoietin and Interleukin-3," <i>Biochemical Pharmacology</i> , 1995, Vol. 50, pp. 413-9.
AY	Goodnough LT, Anderson KC, Kurtz S, et al., "Indications and Guidelines for the Use of Hematopoietic Growth Factors," <i>Transfusion</i> , 1993, Vol. 33, pp. 944-59.
AZ	Harbol AW, Liesveld JL, Simpson-Haidaris PJ, et al., "Mechanisms of Cytopenia in Human Immunodeficiency Virus Infection," <i>Blood Reviews</i> , 1994, Vol. 8, pp. 241-51.
BB	Jelkmann WB, Fandrey J, Frede S, et al., "Inhibition of Erythropoietin Production by Cytokines: Implications for the Anemia Involved in Inflammatory States," <i>Annals of the New York Academy of Sciences</i> , 1994, Vol. 718, pp. 300-9.
	Jen F, Glue P, Gupta S, et al., "Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients with Chronic Hepatitis C," <i>Therapeutic Drug Monitoring</i> , Vol. 22, No. 3, 2000.
BD	Koziel MJ, "Cytokines in Viral Hepatitis," <i>Seminars in Liver Disease</i> , 1999, Vol. 19, pp. 157-69.
BE	Krantz SB, "Erythropoietin," <i>Blood</i> , 1991, Vol. 77, pp. 419-34.
BF	Kuehl AK, Noormohamed SE, "Recombinant Erythropoietin for Zidovudine-Induced Anemia in AIDS," <i>Annals of Pharmacotherapy</i> , 1995, Vol. 29, pp. 778-9.
BG	Lai CM, Swaminathan N, Beilharz MW, et al., "Interferon- $\alpha$ Inhibits Erythropoietin-Induced Proliferation, but Not Differentiation, and Restricts Erythroleukemia Development," <i>Journal of Interferon &amp; Cytokine Research</i> , 1995, Vol. 15, pp. 669-75.
BH	MacDougall DS, "Recombinant Human Erythropoietin for HIV-Related Anemia," <i>Journal of the Int'l Association of Physicians in AIDS Care</i> , Oct. 1998, pp. 18-24.
BI	Marcellin P, Boyer N, Giostra E, et al., "Recombinant Human $\alpha$ -Interferon in Patients with Chronic Non-A, Non-B Hepatitis: A Multicenter Randomized Controlled Trial from France," <i>Hepatology</i> , 1991, Vol. 13, pp. 393-7.
BJ	McHutchison JG, Gordon SC, Schiff ER, et al., "Interferon Alfa-2b Alone or in Combination With Ribavirin as Initial Treatment for Chronic Hepatitis C," <i>New England Journal of Medicine</i> , 1998, Vol. 339, pp. 1485-92.
BK	Means RT, Jr., "Advances in the Anemia of Chronic Disease," <i>Int'l Journal of Hematology</i> , 1999, Vol. 70, pp. 7-12.
BL	Means RT, Jr., "Pathogenesis of the Anemia of Chronic Disease: A Cytokine-Mediated Anemia," <i>Stem Cells</i> , 1995, Vol. 13, pp. 32-7.
BM	Means RT, Jr., Krantz SB, "Progress in Understanding the Pathogenesis of the Anemia of Chronic Disease," <i>Blood</i> , 1992, Vol. 80, pp. 1639-47.
BN	Moore RD, Keruly JC, Chaisson RE, "Anemia and Survival in HIV Infection," <i>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</i> , 1998, Vol. 19, pp. 29-33.
BO	Musto P, Falcone A, D'Arena G, et al., "Clinical Results of Recombinant Erythropoietin in Transfusion-Dependent Patients with Refractory Multiple Myeloma: Role of Cytokines and Monitoring of Erythropoiesis," <i>European Journal of Haematology</i> , 1997, Vol. 58, pp. 314-9.
BP	Napoli J, Bishop GA, McGuinness PH, et al., "Progressive Liver Injury in Chronic Hepatitis C Infection Correlates with Increased Intrahepatic Expression of Th1-Associated Cytokines," <i>Hepatology</i> , 1996, Vol. 24, pp. 759-65.
BQ	Peeters HM, Jongen-Lavrencic M, Vreugdenhil G, et al., "Effect of Recombinant Human Erythropoietin on Anemia and Disease Activity in Patients with Rheumatoid Arthritis and Anaemia of Chronic Disease: A Randomised Placebo Controlled Double Blind 52 Weeks Clinical Trial," <i>Annals of the Rheumatic Diseases</i> , 1996, Vol. 55, pp. 739-44.
BR	Poynard T, Marcellin P, Lee SS, et al., "Randomised Trial of Interferon $\alpha$ 2b Plus Ribavirin for 48 Weeks or For 24 Weeks Versus Interferon $\alpha$ 2b Plus Placebo for 48 Weeks for Treatment of Chronic Infection with Hepatitis C Virus," <i>Lancet</i> , 1998, Vol. 352, pp. 1426-32.
BS	Reichard O, Norkrans G, Fryden A, et al., "Randomized, Double-Blind, Placebo-Controlled Trial of Interferon $\alpha$ -2b With and Without Ribavirin for Chronic Hepatitis C," <i>Lancet</i> , 1998, Vol. 351, pp. 83-7.
BT	Reichard O, Schvarcz R, Weiland O., "Therapy of Hepatitis C: Alpha Interferon and Ribavirin," <i>Hepatology</i> , 1997, Vol. 26 (Supp. 1), pp. 108S-11S.
BU	Spivak JL, Barnes DC, Fuchs E, et al., "Serum Immunoreactive Erythropoietin in HIV-Infected Patients," <i>Journal of the American Medical Association</i> , 1989, Vol. 261, pp. 3104-7.
BV	Thomas HC, Booth J, Brown J., "Pathophysiology and Treatment of Hepatitis C," <i>Drugs</i> , 1996, Vol. 52 (Supp. 2), pp. 1-8.
BW	Weisz K, Goldman D, Talal A, et al., "Interferon (IFN) and Ribavirin (RBV) Therapy for Hepatitis C (HCV) in HIV-Coinfected Patients, 12 Month Follow-Up," 7 <sup>th</sup> Conference on Retroviruses and Opportunistic Infections, Jan. 30-Feb. 2, 2000, Abstract 283.
BX	"Management of Hepatitis C Consensus Development Statement," National Institutes of Health, Mar. 24-26, 1997.
BY	"Rebetron Product Label," <i>Physician's Desk Reference</i> , 53 <sup>rd</sup> Ed., Medical Economics Company, Montvale, NJ, 1999.
EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	2/26/03
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

paper 10.4